title: [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
abstract: In 2013, the Japanese Diet passed the Regenerative Medicine Promotion Act and the revisions to the Pharmaceutical Affairs Act, which was also renamed as the Therapeutic Products Act (TPA). One of the aims of the new/revised Acts is to promote the development and translation of and access to regenerative/cellular therapies. In the TPA, a product derived from processing cells is categorized as a subgroup of "regenerative medicine, cellular therapy and gene therapy products" (RCGPs), products distinct from pharmaceuticals and medical devices, allowing RCGPs to obtain a conditional and time- limited marketing authorization much earlier than that under the conventional system. To foster not only RCGPs, but also innovative pharmaceuticals and medical devices, the Ministry of Health, Labour and Welfare recently launched Translational Research Program for Innovative Pharmaceuticals, Medical Devices and RCGPs. This mini-review introduces contributions of the National Institute of Health Sciences (NIHS) to research projects on RCGPs in the Program.
authors.forename: Yoji
authors.initials: Y
authors.lastname: Sato
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D015316:Genetic Therapy; D006077:Government Agencies; D006298:Health Services Administration; D007564:Japan; D044968:Regenerative Medicine; D057170:Translational Research, Biomedical